Current screening, design, and delivery approaches to address low permeability of chemically synthesized modalities in drug discovery and early clinical development.

[1]  A. Sangamwar,et al.  Supersaturating lipid-based solid dispersion of atazanavir provides enhanced solubilization and supersaturation in the digestive aqueous phase. , 2023, International journal of pharmaceutics.

[2]  Shriya S. Srinivasan,et al.  RoboCap: Robotic mucus-clearing capsule for enhanced drug delivery in the gastrointestinal tract , 2022, Sci. Robotics.

[3]  H. Edlund,et al.  Considerations in the developability of peptides for oral administration when formulated together with transient permeation enhancers. , 2022, International journal of pharmaceutics.

[4]  Hongyu Zhou,et al.  Evaluation of an Ussing Chamber System Equipped with Rat Intestinal Tissues to Predict Intestinal Absorption and Metabolism in Humans , 2022, European Journal of Drug Metabolism and Pharmacokinetics.

[5]  M. Kao,et al.  Novel application of rhein and its prodrug diacerein for reversing cancer-related multidrug resistance through the dual inhibition of P-glycoprotein efflux and STAT3-mediated P-glycoprotein expression. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[6]  Yuan Chen,et al.  Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective , 2022, Pharmaceutical Research.

[7]  Liang Wang,et al.  PBPK Modeling on Organs-on-Chips: An Overview of Recent Advancements , 2022, Frontiers in Bioengineering and Biotechnology.

[8]  M. Bermejo,et al.  Exploring the Predictive Power of the In Situ Perfusion Technique towards Drug Absorption: Theory, Practice, and Applications. , 2022, Molecular pharmaceutics.

[9]  M. Riyazuddin,et al.  Approaches to minimize the effects of P‐glycoprotein in drug transport: A review , 2022, Drug development research.

[10]  A. Baidya,et al.  Structural modification aimed for improving solubility of lead compounds in early phase drug discovery. , 2022, Bioorganic & medicinal chemistry.

[11]  S. Skolnik,et al.  Discovery solubility measurement and assessment of small molecules with drug development in mind. , 2022, Drug discovery today.

[12]  M. Novič,et al.  Structure–Function Relationships in the Human P-Glycoprotein (ABCB1): Insights from Molecular Dynamics Simulations , 2021, International journal of molecular sciences.

[13]  W. D. de Jonge,et al.  The Progress of Intestinal Epithelial Models from Cell Lines to Gut-On-Chip , 2021, International journal of molecular sciences.

[14]  T. Shinozawa,et al.  Human Organoids for Predictive Toxicology Research and Drug Development , 2021, Frontiers in Genetics.

[15]  Luoran Shang,et al.  Smart ingestible devices: Orally delivering macromolecules and beyond , 2021, Matter.

[16]  Huanhuan Wang,et al.  A versatile modular preparation strategy for targeted drug delivery systems against multidrug-resistant cancer cells , 2021, Nanotechnology.

[17]  K. Giacomini,et al.  Interaction of Commonly Used Oral Molecular Excipients with P-glycoprotein , 2021, The AAPS Journal.

[18]  C. Porter,et al.  Lipophilic Conjugates of Drugs: A Tool to Improve Drug Pharmacokinetic and Therapeutic Profiles , 2021, Pharmaceutical Research.

[19]  N. Roxhed,et al.  Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors , 2021, Nature Biotechnology.

[20]  A. Dalpiaz,et al.  Targeting Systems to the Brain Obtained by Merging Prodrugs, Nanoparticles, and Nasal Administration , 2021, Pharmaceutics.

[21]  G. Gabriel,et al.  Gut-on-a-chip: Mimicking and monitoring the human intestine. , 2021, Biosensors & bioelectronics.

[22]  Vasanthanathan Poongavanam,et al.  Steering New Drug Discovery Campaigns: Permeability, Solubility, and Physicochemical Properties in the bRo5 Chemical Space. , 2021, ACS medicinal chemistry letters.

[23]  David J Brayden,et al.  Comparison of the effects of the intestinal permeation enhancers, SNAC and sodium caprate (C10): isolated rat intestinal mucosae and sacs. , 2020, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[24]  H. Gill,et al.  A crossover clinical study to evaluate pain intensity from microneedle insertion in different parts of the oral cavity. , 2020, International journal of pharmaceutics.

[25]  S. Ben-Shabat,et al.  Prodrugs for Improved Drug Delivery: Lessons Learned from Recently Developed and Marketed Products , 2020, Pharmaceutics.

[26]  K. Maeda,et al.  Characterization of the Human Intestinal Drug Transport with Ussing Chamber System Incorporating Freshly Isolated Human Jejunum , 2020, Drug Metabolism And Disposition.

[27]  S. Basu,et al.  Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective , 2020, The AAPS Journal.

[28]  L. Benet,et al.  The Critical Role of Passive Permeability in Designing Successful Drugs , 2020, ChemMedChem.

[29]  R. Norton,et al.  Improving membrane permeation in the beyond rule-of-five space by using prodrugs to mask hydrogen bond donors. , 2020, ACS chemical biology.

[30]  Martín G. Martín,et al.  Gut-on-a-chip: Current progress and future opportunities. , 2020, Biomaterials.

[31]  S. Kume,et al.  Generation of intestinal organoids derived from human pluripotent stem cells for drug testing , 2020, Scientific Reports.

[32]  A. Haeri,et al.  Nanoformulation strategies for improving intestinal permeability of drugs: A more precise look at permeability assessment methods and pharmacokinetic properties changes. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[33]  Vasanthanathan Poongavanam,et al.  Solution conformations explain the chameleonic behaviour of macrocyclic drugs. , 2020, Chemistry.

[34]  Venkata R. Krishnamurthy,et al.  The Evolving Druggability and Developability Space: Chemically Modified New Modalities and Emerging Small Molecules , 2020, The AAPS Journal.

[35]  Robert Langer,et al.  A luminal unfolding microneedle injector for oral delivery of macromolecules , 2019, Nature Medicine.

[36]  G. Camenisch,et al.  Examining P‐gp efflux kinetics guided by the BDDCS ‐ Rational selection of in vitro assay designs and mathematical models , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[37]  Y. Kalia,et al.  Drug Transport across Porcine Intestine Using an Ussing Chamber System: Regional Differences and the Effect of P-Glycoprotein and CYP3A4 Activity on Drug Absorption , 2019, Pharmaceutics.

[38]  David J Brayden,et al.  Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C10) , 2019, Pharmaceutics.

[39]  David J Brayden,et al.  Application of Permeation Enhancers in Oral Delivery of Macromolecules: An Update , 2019, Pharmaceutics.

[40]  S. Ben-Shabat,et al.  Lipidic prodrug approach for improved oral drug delivery and therapy , 2018, Medicinal research reviews.

[41]  Jennifer Dressman,et al.  A Refined Developability Classification System. , 2018, Journal of pharmaceutical sciences.

[42]  Vasanthanathan Poongavanam,et al.  Impact of Dynamically Exposed Polarity on Permeability and Solubility of Chameleonic Drugs Beyond the Rule of 5. , 2018, Journal of medicinal chemistry.

[43]  J. Rosenstock,et al.  Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial , 2017, JAMA.

[44]  M. Wendt,et al.  Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection. , 2017, Journal of medicinal chemistry.

[45]  S. Mitragotri,et al.  Intestinal micropatches for oral insulin delivery , 2017, Journal of drug targeting.

[46]  Vivek Dave,et al.  Current and evolving approaches for improving the oral permeability of BCS Class III or analogous molecules , 2017, Drug development and industrial pharmacy.

[47]  M. Shalaeva,et al.  Relationship between Passive Permeability and Molecular Polarity Using Block Relevance Analysis. , 2017, Molecular pharmaceutics.

[48]  P. Artursson,et al.  Oral absorption of peptides and nanoparticles across the human intestine: Opportunities, limitations and studies in human tissues. , 2016, Advanced drug delivery reviews.

[49]  David J Brayden,et al.  Intestinal permeation enhancers for oral peptide delivery. , 2016, Advanced drug delivery reviews.

[50]  Laura M Ensign,et al.  Nanoparticles for oral delivery: Design, evaluation and state-of-the-art. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[51]  G. Caron,et al.  Molecular descriptors for polarity: the need for going beyond polar surface area. , 2016, Future medicinal chemistry.

[52]  T. Murakami.  A Minireview: Usefulness of Transporter-Targeted Prodrugs in Enhancing Membrane Permeability. , 2016, Journal of pharmaceutical sciences.

[53]  E. Chow,et al.  Using Physiologically Based Pharmacokinetic (PBPK) Modeling to Evaluate the Impact of Pharmaceutical Excipients on Oral Drug Absorption: Sensitivity Analyses , 2016, The AAPS Journal.

[54]  J. Kihlberg,et al.  Macrocyclic Prodrugs of a Selective Nonpeptidic Direct Thrombin Inhibitor Display High Permeability, Efficient Bioconversion but Low Bioavailability. , 2016, Journal of medicinal chemistry.

[55]  Xiaomei Zhuang,et al.  PBPK modeling and simulation in drug research and development , 2016, Acta pharmaceutica Sinica. B.

[56]  Paul D Leeson,et al.  Molecular inflation, attrition and the rule of five. , 2016, Advanced drug delivery reviews.

[57]  David J Brayden,et al.  Safety concerns over the use of intestinal permeation enhancers: A mini-review , 2016, Tissue barriers.

[58]  M. Chung,et al.  The Prodrug Approach: A Successful Tool for Improving Drug Solubility , 2015, Molecules.

[59]  Robert Langer,et al.  Microneedles for drug delivery via the gastrointestinal tract. , 2015, Journal of pharmaceutical sciences.

[60]  Fabrizio Giordanetto,et al.  Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. , 2014, Chemistry & biology.

[61]  Dima Kozakov,et al.  How Proteins Bind Macrocycles , 2014, Nature chemical biology.

[62]  Jakir Pinjari,et al.  THE IMPACT OF PERMEABILITY ENHANCERS ON ASSESSMENT FOR MONOLAYER OF COLON ADENOCARCINOMA CELL LINE (CACO-2) USED IN IN VITRO PERMEABILITY ASSAY , 2013 .

[63]  A. Dahan,et al.  Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach , 2012, Expert opinion on drug delivery.

[64]  H. Maag.  Overcoming poor permeability - the role of prodrugs for oral drug delivery. , 2012, Drug discovery today. Technologies.

[65]  J. Rautio,et al.  Prodrugs - an efficient way to breach delivery and targeting barriers. , 2011, Current topics in medicinal chemistry.

[66]  Jennifer B Dressman,et al.  The developability classification system: application of biopharmaceutics concepts to formulation development. , 2010, Journal of pharmaceutical sciences.

[67]  Wolfgang Löscher,et al.  Differences in the expression of endogenous efflux transporters in MDR1‐transfected versus wildtype cell lines affect P‐glycoprotein mediated drug transport , 2010, British journal of pharmacology.

[68]  Suzanne Skolnik,et al.  Mitigating permeability-mediated risks in drug discovery , 2010, Expert opinion on drug metabolism & toxicology.

[69]  David J Brayden,et al.  Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. , 2009, Advanced drug delivery reviews.

[70]  G. Amidon,et al.  Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. , 2009, Molecular pharmaceutics.

[71]  Tycho Heimbach,et al.  Prodrugs: design and clinical applications , 2008, Nature Reviews Drug Discovery.

[72]  V. Stella,et al.  Prodrug strategies to overcome poor water solubility. , 2007, Advanced drug delivery reviews.

[73]  Andreas Reichel,et al.  Development and Application of Physiologically Based Pharmacokinetic‐Modeling Tools to Support Drug Discovery , 2005, Chemistry & biodiversity.

[74]  Li Di,et al.  Application of pharmaceutical profiling assays for optimization of drug-like properties. , 2005, Current opinion in drug discovery & development.

[75]  Lawrence X. Yu,et al.  Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability. , 2005, Molecular pharmaceutics.

[76]  Longqin Hu.  Prodrugs: effective solutions for solubility, permeability and targeting challenges. , 2004, IDrugs : the investigational drugs journal.

[77]  Antony D'Emanuele,et al.  The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[78]  Li Di,et al.  Pharmaceutical profiling in drug discovery. , 2003, Drug discovery today.

[79]  Donald W. Miller,et al.  In vitro and in vivo models for assessing drug efflux transporter activity. , 2003, Advanced drug delivery reviews.

[80]  A. Mitra,et al.  Current prodrug strategies via membrane transporters/receptors , 2002, Expert opinion on biological therapy.

[81]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[82]  J. Polli,et al.  Rational use of in vitro P-glycoprotein assays in drug discovery. , 2001, The Journal of pharmacology and experimental therapeutics.

[83]  P. Selzer,et al.  Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.

[84]  H Lennernäs,et al.  Membrane transport of drugs in different regions of the intestinal tract of the rat. , 1998, Journal of pharmaceutical sciences.

[85]  S. Nylander,et al.  Jejunal Permeability: A Comparison Between the Ussing Chamber Technique and the Single-Pass Perfusion in Humans , 1997, Pharmaceutical Research.

[86]  Hans Lennernäs,et al.  Comparison Between Permeability Coefficients in Rat and Human Jejunum , 1996, Pharmaceutical Research.

[87]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[88]  Z. Ates-Alagoz,et al.  Prodrugs , 2021, Remington.

[89]  Matthew L. Danielson,et al.  In Silico ADME Techniques Used in Early-Phase Drug Discovery , 2017 .

[90]  S. Clas,et al.  Chemistry-enabled drug delivery (prodrugs): recent progress and challenges. , 2014, Drug discovery today.

[91]  P. Annaert,et al.  In Vitro Screening Models to Assess Intestinal Drug Absorption and Metabolism , 2008 .

[92]  Thomas J. Raub,et al.  P-glycoprotein recognition of substrates and circumvention through rational drug design. , 2006, Molecular pharmaceutics.

[93]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.